Itanistomig  (Synonyms: LB-101)

Itanistomig (LB-101) is a tetravalent bispecific antibody targeting PD-L1 and CD47. Itanistomig blocks PD-L1 and achieves tumor enrichment through binding to PD-L1, and also exerts conditional CD47 blocking activity via cleavage of the hinge linker in the PD-L1-positive tumor microenvironment. Itanistomig induces antibody-dependent cellular phagocytosis in human CD14⁺ cells and drives tumor regression. Itanistomig can be used in research related to solid tumors^[1][2].

(VH-G1CH1-h)-H-gamma1_L-kappa-L-kappa

Human

CD274 & CD47

Itanistomig strongly enhances antibody-dependent cellular phagocytosis by human CD14+ cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Itanistomig (administered systemically at equimolar doses with Atezolizumab (HY-P9904)) eradicates tumors in 87.5% of MC38 hPD-L1⁺ syngeneic mouse models, and induces durable anti-tumor immunity to prevent tumor growth upon rechallenge^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

29126  [NCBI] & 16423  [NCBI]

Q9NZQ7 & Q61735-1

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

243.635 kDa

2923687-56-1

Liquid

Colorless to light yellow

[Itanistomig]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  G1-Fab-kappa-IgG1-kappa

• 
  Immobilized PD-L1 Protein, Human (HEK293, HY-P72917) can bind Itanistomig. The EC₅₀ for this effect is 129.7 ng/mL.
• 
  Immobilized FCGRT Protein, Human (GST, HY-P73361) can bind Itanistomig. The EC₅₀ for this effect is 57.01 ng/mL.

• [1]. Finlay J, et al. LB101, a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody (mAb), combines tumor microenvironment (TME) targeted delivery (PD-L1) and a single biological high potency effector (CD47).
  

  [2]. Brinkmann U, et al. The making of multispecific immunoglobulins - a clinical perspective. MAbs. 2026;18(1):2613548.  [Content Brief]